Oncology solutions company Massive Bio has risen to the challenge of developing a new AI-fueled drug-matching technology that will be vital to oncologists’ process of identifying additional cancer treatment options for patients. Crucially, this AI will bring recently approved drugs to a wider range of treatment plans as well as help match patients with active clinical trials that might benefit their specific needs. This will do much to lighten the load for overburdened oncology clinicians, who typically pore over treatment options in light of each patient’s unique data points, while also retaining the influence of an important element: human touch.
“We believe there’s so much more that can be done to advance the field of oncology,” said Selin Kurnaz, Massive Bio’s Co-Founder and Chief Executive Officer. “We want to reverse engineer the process using real-time clinical data — not outdated financial claims data — to match the right patients with the right treatments at the right time.” The company’s Chief Technology Officer as well as Chief Operating Officer, Cagatay Culcuoglu, points to AI and machine learning technology as fundamental to lessening the financial burden of generic, non-precision-based therapies.
The presence of AI and biomarker testing in the oncology space has steadily been on the rise, with roughly 55% of clinical trials for various cancers employing biomarkers. However, the myriad challenges related to effective biomarker integration in clinical care settings has put the kibosh on patients getting the highly effective, tailor-made treatments they need.
The drug-matching platform is set for its initial launch sometime in the first half of the year, with wider availability on the table for just ahead of 2024.
